Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Amazon Explores AI Content Marketplace With Media Publishers 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
CARLSBAD, Calif., Feb. 21, 2018 -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that the Company plans to participate in two upcoming investor conferences.
- March 1, 2018, GenMark’s management is scheduled to participate in the BTIG Snowbird Healthcare Conference in Snowbird, UT. Due to the format of this event, no webcast is available.
- March 14, 2018 at 10:00am ET, GenMark’s management is scheduled to present at the Cowen & Co. 38th Annual Health Care Conference in Boston, MA. Interested parties can access the live and archived webcast at www.genmarkdx.com, under the investor relations section.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ:GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
